Transurethral Ultrasound Ablation a Promising Prostate Cancer …
Oct 14, 2024 · Patients with prostate cancer demonstrated reduced tumor volume and PSA levels, a key marker of prostate cancer progression, and experienced improved urinary function and maintained sexual function after undergoing Transurethral Ultrasound Ablation (TULSA), according to a study presented at the CURE® Educated Patient® Prostate Cancer Summit by Dr. Yair Lotan, a professor of urology at UT ...
How I Used Turkey Tail Mushrooms Alongside Cancer Treatment
Jan 8, 2024 · At first, I ordered little vials of tincture online. There are plenty of companies that make and sell tincture, a concoction of alcohol imbued or infused with the essence of some plant, herb, or, in this case, mushroom.
Long-Term Study Data Support Keytruda as Standard of Care for …
Oct 1, 2024 · A 10-year follow-up data from the KEYNOTE-006 study showed that Keytruda continued to outperform Yervoy in terms of overall survival, progression-free survival, and melanoma-specific survival for patients with advanced melanoma.
Surrendering to God: How My Faith Led to Healing From Cancer
Aug 8, 2024 · Cancer is a word that strikes fear into the hearts of many. It conjures images of suffering, loss and a battle that often feels unwinnable. For me, cancer wasn’t just a distant concept; it was my reality.
6 FDA Cancer Approvals from August 2024 - Curetoday
In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.
FDA Grants Priority Review to Enhertu for HER2-Low and -Ultralow …
Oct 3, 2024 · The Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental biologics license application for Enhertu (trastuzumab deruxtecan) to treat patients with unresectable or metastatic HER2-low or -ultralow breast cancer treated with at least one endocrine therapy in the metastatic setting.
Treatment Options for Recurrent Prostate Cancer
Nov 11, 2024 · Panelists discuss how implementing targeted strategies can promote equity in treatment for all patients, while offering practical advice for those facing barriers to accessing necessary care for advanced prostate cancer.
FDA Approval of Trodelvy Withdrawn for Urothelial Carcinoma
Oct 22, 2024 · Trodelvy received accelerated approval from the FDA in April 2021 for this specific indication, which was based on findings from the phase 2 TROPHY-U-01 study, which focused on findings related to the tumor response rate and duration of response. The FDA noted that the continued approval of Trodelvy for locally advanced or metastatic urothelial cancer would be contingent on the confirmatory ...
Esophagitis: A Common Radiation Side Effect - Curetoday
Mar 24, 2005 · Radiation-induced esophagitis, the inflammation of the esophagus, is an unpleasant but temporary side effect of radiation therapy. Esophagitis is common in people who receive radiation therapy to the chest area for cancer of the esophagus as well as other cancers, including lung cancer and lymphoma.
Years Later, the Decision to Walk Away from Aromatase
Apr 24, 2021 · “It’s been almost seven years since I made the decision to stop taking aromatase inhibitors and I’m happy to report I’m feeling great,” writes a cancer survivor. “There are no more unwanted side effects. The decision to stop taking the medication was right for me.”